Atrial fibrillation patients saw 69% lower risk with common blood thinners
Direct oral anticoagulants cut the risk of serious clinical events by 69% in atrial fibrillation patients with an intermediate risk of stroke, according to the randomized SINGLE-AF trial. The benefit was driven mainly by fewer ischemic strokes, with no increase in major bleeding.
Newer blood thinners significantly lower serious cardiovascular event risk for atrial fibrillation patients, according to a large randomized trial. Conducted by Professor Boyoung Joung of Yonsei University, the SINGLE-AF trial, presented at ESC Congress 2026, discovered a 69% reduction in primary endpoint events among patients taking direct oral anticoagulants (DOACs).
The primary endpoint combined stroke, systemic embolism, major bleeding, and cardiovascular death. Compared with no anticoagulant therapy, DOAC treatment was associated with fewer adverse clinical events, particularly ischemic strokes. Major bleeding occurred less frequently in the DOAC group. The findings support the use of DOACs for intermediate-risk atrial fibrillation patients, potentially guiding future guideline recommendations and insurance policies.
Written by urgent.news from ScienceDaily's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
